«
While immune checkpoint blockade therapy is effective in many cancers, it has been less successful for this particular form of prostate cancer, which has motivated a search for targeted therapies that overcome this resistance.»
Not exact matches
Their study of fecal samples from 105 patients treated with
immune checkpoint blockade indicates that certain characteristics of patients» microbiomes correlate with slower disease progression
while other qualities are associated with rapid worsening of the disease.
Researchers led by Van Allen and Choueiri sought an explanation for why some patients with a form of metastatic kidney cancer called clear cell renal cell cancer (ccRCC) gain clinical benefit — sometimes durable — from treatment with
immune checkpoint inhibitors that block the PD - 1
checkpoint,
while other patients don't.